Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Commentary
  • Published:

Trisomy 21 leukemias: finding the hits that matter

Oncogene volume 29, pages 6099–6101 (2010)Cite this article

Subjects

Abstract

Down syndrome is associated with a markedly increased risk of childhood leukemias, and identification of chromosome 21 sequences that have a role in leukemogenesis may provide insights into critical pathways and suggest targets for therapy and prevention. A study in this issue of Oncogene, defines human chromosome 21 sequences that alter hematopoiesis and induce expression of leukemia-associated markers.

This is a preview of subscription content, access via your institution

Relevant articles

Open Access articles citing this article.

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

References

  • Alford KA, Slender A, Vanes L, Li Z, Fisher EM, Nizetic D et al. (2010). Perturbed hematopoiesis in the Tc1 mouse model of Down syndrome. Blood 115: 2928–2937.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Chou ST, Opalinska JB, Yao Y, Fernandes MA, Kalota A, Brooks JS et al. (2008). Trisomy 21 enhances human fetal erythro-megakaryocytic development. Blood 112: 4503–4506.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • De Vita S, Canzonetta C, Mulligan C, Delom F, Groet J, Baldo C et al. (2010). Trisomic dose of several chromosome 21 genes perterbs hematopoietic stem and progenitor cell differentiation in Down syndrome. Oncogene 29: 6102–6114.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Izraeli S, Rainis L, Hertzberg L, Smooha G, Birger Y . (2007). Trisomy of chromosome 21 in leukemogenesis. Blood Cells Mol Dis 39: 156–159.

    Article  CAS  PubMed  Google Scholar 

  • Kirsammer G, Jilani S, Liu H, Davis E, Gurbuxani S, Le Beau MM et al. (2008). Highly penetrant myeloproliferative disease in the Ts65Dn mouse model of Down syndrome. Blood 111: 767–775.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Klusmann JH, Li Z, Bohmer K, Maroz A, Koch ML, Emmrich S et al. (2010). miR-125b-2 is a potential oncomiR on human chromosome 21 in megakaryoblastic leukemia. Genes Dev 24: 478–490.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Li Z, Godinho FJ, Klusmann JH, Garriga-Canut M, Yu C, Orkin SH . (2005). Developmental stage-selective effect of somatically mutated leukemogenic transcription factor GATA1. Nat Genet 37: 613–619.

    Article  CAS  PubMed  Google Scholar 

  • Malinge S, Izraeli S, Crispino JD . (2009). Insights into the manifestations, outcomes, and mechanisms of leukemogenesis in Down syndrome. Blood 113: 2619–2628.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Ng AP, Hyland CD, Metcalf D, Carmichael CL, Loughran SJ, Di Rago L et al. (2010). Trisomy of Erg is required for myeloproliferation in a mouse model of Down syndrome. Blood 115: 3966–3969.

    Article  CAS  PubMed  Google Scholar 

  • Salek-Ardakani S, Smooha G, de Boer J, Sebire NJ, Morrow M, Rainis L et al. (2009). ERG is a megakaryocytic oncogene. Cancer Res 69: 4665–4673.

    Article  CAS  PubMed  Google Scholar 

  • Tunstall-Pedoe O, Roy A, Karadimitris A, de la Fuente J, Fisk NM, Bennett P et al. (2008). Abnormalities in the myeloid progenitor compartment in Down syndrome fetal liver precede acquisition of GATA1 mutations. Blood 112: 4507–4511.

    Article  CAS  PubMed  Google Scholar 

  • Yanagida M, Osato M, Yamashita N, Liqun H, Jacob B, Wu F et al. (2005). Increased dosage of Runx1/AML1 acts as a positive modulator of myeloid leukemogenesis in BXH2 mice. Oncogene 24: 4477–4485.

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Child Health Institute of New Jersey, University of Medicine and Dentistry of New Jersey (UMDNJ), Robert Wood Johnson Medical School (RWJMS), New Brunswick, NJ, USA

    A B Rabson

  2. Department of Pediatrics, UMDNJ-RWJMS, New Brunswick, NJ, USA

    A B Rabson

  3. Department of Molecular Genetics, Microbiology and Immunology, UMDNJ-RWJMS, New Brunswick, NJ, USA

    A B Rabson

  4. Department of Pathology and Laboratory Medicine, UMDN-RWJMS, New Brunswick, NJ, USA

    A B Rabson

  5. Cancer Institute of New Jersey, UMDNJ-RWJMS, New Brunswick, NJ, USA

    A B Rabson

Authors
  1. A B Rabson
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to A B Rabson.

Ethics declarations

Competing interests

The author declares no conflict of interest.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Rabson, A. Trisomy 21 leukemias: finding the hits that matter. Oncogene 29, 6099–6101 (2010). https://doi.org/10.1038/onc.2010.353

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/onc.2010.353

This article is cited by

Search

Advanced search

Quick links